In vivo studies demonstrate that FerroBio-isolated cells show significantly better engraftment in animal models. At the highest CD34+ dose, early animal study results shows that FerroBio achieved a 100% engraftment rate versus 67% with competing methods—highlighting the biological advantage and therapeutic promise of our cell preparations